iSpecimen Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
iSpecimen Inc. (ISPC) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $680 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-04-01
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-03-31 was $680.00.
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $680.00.
- iSpecimen Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $0.00 derived: sum of 2 quarters · filed 2026-04-01 | $0.00 derived: sum of 3 quarters · filed 2026-04-01 | $680.00 10-K · filed 2026-04-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $680.00 10-Q · filed 2024-11-07 | $680.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $680.00 10-Q · filed 2024-08-06 | $680.00 derived: sum of 3 quarters · filed 2024-08-06 | $680.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $680.00 10-Q · filed 2024-05-07 | $680.00 derived: sum of 2 quarters · filed 2024-05-07 | $680.00 derived: sum of 3 quarters · filed 2024-11-07 | $680.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2024-11-07 | $0.00 10-K · filed 2024-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |